Syndax Pharmaceuticals (SNDX) Free Cash Flow (2015 - 2026)

Syndax Pharmaceuticals' Free Cash Flow history runs 12 years deep, the most recent figure standing at -$50.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 47.1% year-over-year to -$50.3 million; the TTM figure through Mar 2026 stood at -$278.2 million (up 2.9% YoY), while the FY2025 annual figure was -$323.2 million, down 17.56% from the prior year.
• Free Cash Flow was -$50.3 million for Q1 2026 at Syndax Pharmaceuticals, up from -$69.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$22.9 million in Q4 2022 to a low of -$95.2 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$55.4 million across 5 years, with a median of -$50.3 million in 2026.
• The sharpest annual moves came in 2022 and 2026: Free Cash Flow tumbled 122.73% in 2022, then soared 47.1% in 2026.
• A 5-year view of Free Cash Flow shows it stood at -$22.9 million in 2022, then plunged by 80.61% to -$41.3 million in 2023, then slumped by 38.79% to -$57.4 million in 2024, then retreated by 21.18% to -$69.5 million in 2025, then grew by 27.61% to -$50.3 million in 2026.
• The last three Free Cash Flow figures came in at -$50.3 million (Q1 2026), -$69.5 million (Q4 2025), and -$70.5 million (Q3 2025), per Business Quant data.